Business
Quince Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results
SOUTH SAN FRANCISCO, Calif., May 13, 2025--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today provided an update on the company’s development pipeline and reported financial results for the first quarter ended March 31, 2025.
About this update from Quince Therapeutics, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1121,"height":442,"url":"https://media.zenfs.com/en/business-wire.com/45e7ca740672285e16611fc059cd100b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/G81osY4sK1Rn7pGMP2FMfQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM3OTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/45e7ca740672285e16611fc059cd100b","width":960,"height":379},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/uRHV4WHlQJO6gqi4yTWIVw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIyNDI7aD04ODQ7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/45e7ca740672285e16611fc059cd100b","width":1121,"height":442}},"lazy":false},{"type":"text","content":"Plan to potentially conclude enrollment early for Phase 3 NEAT clinical trial in Ataxia-Telangiectasia (A-T) to align topline results with existing cash runway","length":159,"tagName":"p","attribs":{}},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., May 13, 2025--(BUSINESS WIRE)--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today provided an update on the company’s development pipeline and reported financial results for the first quarter ended March 31, 2025.","length":370,"tagName":"p"},{"type":"text","content":"Dirk Thye, M.D., Quince’s Chief Executive Officer and Chief Medical Officer, said, "In light of current cash runway and with the goal of maximizing a capital efficient development plan, Quince has made the strategic business decision to potentially conclude enrollment of our pivotal Phase 3 NEAT clinical trial early by the end of June 2025 absent additional funding to extend our cash runway beyond the first quarter of 2026. Several factors contributed to this shift in strategy, including slower than anticipated enrollment, uncertain macroeconomic environment, challenging academic site environment, and an operationally well-executed study with limited withdrawals and low rates of missing data and procedural deviations. The combination of these factors leads us to now consider concluding enrollment prior to reaching the pre-specified target of 86 patients in the primary analysis population.","length":906,"tagName":"p"},{"type":"text","content":""It i...